Product
BRII-835
2 clinical trials
3 indications
Indication
Chronic Hepatitis BIndication
Hepatitis BIndication
ChronicClinical trial
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) InfectionStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) InfectionStatus: Completed, Estimated PCD: 2023-07-04